|
Rigel Pharmaceuticals Inc (NASDAQ: RIGL) |
|
Rigel Pharmaceuticals Inc
RIGL's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Rigel Pharmaceuticals Inc growth rates, revenue grew
by 80.58 % in the first quarter of 2025 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.5 %
Rigel Pharmaceuticals Inc realized net income compared to net loss a year ago in first quarter of 2025
• More on RIGL's Growth
|
|
Rigel Pharmaceuticals Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Rigel Pharmaceuticals Inc PEG ratio is at -0.05
Company is currently trading with Price to Cash flow multiple of 18.45 in trailing twelve-month period. |
Company |
9.98 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.84.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.
• More on RIGL's Valuation
|
|
|
|
|
Rigel Pharmaceuticals Inc current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.
Rigel Pharmaceuticals Inc PEG ratio is at -0.05
Company is currently trading with Price to Cash flow multiple of 18.45 in trailing twelve-month period. |
Company |
9.98 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.84.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.49.
Rigel Pharmaceuticals Inc Price to Book Ratio is at 20.08 lower than Industry Avg. of 35.2. and higher than S&P 500 Avg. of 0.01
• More on RIGL's Valuation
|
|
RIGL's Profitability Comparisons
|
Rigel Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 23.95 % from 28.92 % in IV. Quarter.
Rigel Pharmaceuticals Inc net profit margin of 21.46 % is currently ranking no. 29 in Major Pharmaceutical Preparations industry, ranking no. 51 in Healthcare sector and number 623 in S&P 500.
Profitability by Segment |
Total |
21.46 % |
|
|
Rigel Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 23.95 % from 28.92 % in IV. Quarter.
Rigel Pharmaceuticals Inc net profit margin of 21.46 % is currently ranking no. 29 in Major Pharmaceutical Preparations industry, ranking no. 51 in Healthcare sector and number 623 in S&P 500.
• More on RIGL's Key Ratios
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com